|
|
Medical Advisory BoardDavid Sherr, PhD Since 1993, David Sherr's laboratory has conducted research on how common environmental pollutants act like immunosuppressive drugs, compromising immune responses and altering immune cell development–work that has its roots in Dr. Sherr’s graduate studies on the ontogeny of lymphocyte development. Today his lab uses technologies including bone marrow cultures and transgenic mice. Dr. Sherr is also conducting studies related to the molecular mechanisms that initiate and maintain breast cancer. These studies focus on the role of an environmental chemical receptor (the AhR) in dysregulated tumor cell growth and resistance to death signals. A third area of investigation centers on the use of molecular and computational technologies to identify protein fragments useful for vaccination against several types of cancer. Dr. Sherr came to BUSPH from the faculty of Harvard Medical School, where he had earlier been a postdoctoral fellow in the department of Nobel Laureate Baruj Benacerraf. The Sherr Laboratory is funded by research grants from the National Institute of Environmental Health Sciences, the National Heart, Lung, and Blood Institute, the EPA’s Superfund Basic Research Program, and the Avon Corporation. Dr. Sherr is a member of the Boston University Immunology Training Program, the Amyloid Treatment Research Program, the Hematology/Oncology Training Program and is director of the Boston Medical Campus Flow Cytometry Facility. Janet Colantuono Most recently Janet Colantuono was the co-founder and executive director of Hurricane Voices Breast Cancer Foundation. Since its inception in 2001, Janet defined the strategic direction and implemented the Foundation's varied initiatives and projects. Janet brought a unique dedication to Hurricane Voices as seen in her powerful interpretation and implementation of the Foundation's vision and strategy. Her long-term commitment to community service and philanthropic events currently includes participating on the grants review board for Art beCAUSE, and as associate trustee of The Colantuono DeAngelis Scholarship Trust Fund. Angela L. Mellon, M.A. Angela L. Mellon earned her M.A. in biology from Harvard University and is a Clinical Research Consultant at Mentara, Inc. She has 20 years of experience in the biotechnology and pharmaceutical industry ranging from bench research to the management of clinical and laboratory operations for global clinical trials. Ms. Mellon has worked extensively in areas of infectious diseases, gene and cell-based therapeutics, oncology and neurologic disorders, including Alzheimer's and Parkinson's diseases. She has implemented GLP operations, managed clinical testing and data management for companies conducting early stage through pivotal Phase III clinical trials, provided GCP training courses, and performed GCP and GLP audits. In this work Ms. Mellon held responsibilities in project management, clinical operations, assay development, validation and transfer, clinical testing, data management, quality control and quality assurance. In addition, she specializes in the design and implementation of tracking strategies for specimen and data management that result in the facilitation of clinical studies and decrease the time from study start up to database closure. Susan Troyan, M.D. Susan Troyan, M.D. is the Surgical Director of the BreastCare Center and associate surgeon at Boston's Beth Israel Deaconess Medical Center and also an Instructor in Surgery at Harvard Medical School. Dr. Troyan is frequent guest lecturer on breast cancer, women's health and related issues in a variety of forums, both political and medical. In addition to her full-time clinical practice in the surgical evaluation and treatment of breast diseases, she teaches medical students from Harvard Medical School, and residents training at Beth Israel Deaconess Medical Center. Dr. Troyan is involved in clinical research with her major interests involving the intraductal approach to the evaluation and treatment of breast diseases, the cosmetic results of breast conservation, and the use of near infra-red light to aid in guiding surgery. She is a member of LLuminari, a network of America’s best-known doctors and women’s health experts dedicated to health education. Dr. Troyan has been very active in advocacy issues surrounding breast cancer as a past member of the Massachusetts Breast Cancer Coalition Board of Directors and alternate member of the National Breast Cancer Coalition (NBCC) Board of Directors. Dr. Troyan is a core faculty member developing curriculum and teaching at Project Lead, NBCC’s innovative science program for breast cancer activists. She has also worked with the NBCC on their Breast Cancer Quality Care Initiative. She has worked with the Boston Women’s Health Book Collective with the revisions of Our Bodies, Ourselves since 1990. |
